Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think a qualified company like srne will know what they are doing. You don't go to all that trouble just to be told by the fda, hey that's not how it works. This is not a kindergarten ...
Nothing changed ...
SRNE Short Interest
SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER
03/15/2021 56,069,379 12,038,408 4.657541
02/26/2021 56,944,678 11,890,850 4.788949
02/12/2021 64,146,101 20,352,665 3.15173nged ...
Yes, what should I answer you now on a share board, with an essay or with a presentation. Perhaps only so much, I am 65 years old and washed with many waters and was always socio-politically active and what is the most important, I am a father of two adult children and waiting hopefully for many grandchildren. And most importantly, I want to leave my grandchildren a planet on which they can live well. And you know what the worst thing is, I know that they will not have it better than me and that makes me very sad. Ok let's look again at our stock-baby ...
Communism ala marx and engels is not bad in terms of doctrine and principle. What russia and the german democratic republic - DDR - made of it was a dictatorship and they called it communism. And we in germany and the usa seem to live in a liberal democracy, but I call it capitalism. Okay, if I had to choose, I really have a choice. The most important thing is, we have to save our planet and then let's see ...
All this talk about srne not being recognized is far from reality. If it were not for the shortie pigs, we would be one hundred percent far, far higher at this potential.
Wow, what a market ...
04/01/2021 8:53:03 EDT I 8.27 5
04/01/2021 8:53:03 EDT I 8.28 5
04/01/2021 8:52:40 EDT T 8.28 197
04/01/2021 8:52:40 EDT I 8.26 1
04/01/2021 8:52:40 EDT I 8.26 1
04/01/2021 8:52:40 EDT I 8.26 1
04/01/2021 8:52:40 EDT I 8.27 5
04/01/2021 8:52:40 EDT I 8.27 7
04/01/2021 8:52:40 EDT I 8.28 1
04/01/2021 8:52:40 EDT I 8.28 1
04/01/2021 8:52:40 EDT I 8.28 1
04/01/2021 8:52:40 EDT T 8.28 211
04/01/2021 8:52:40 EDT I 8.27 3
04/01/2021 8:52:40 EDT I 8.28 35
04/01/2021 8:52:40 EDT I 8.27 1
04/01/2021 8:52:40 EDT I 8.29 37
Ok my friend, the problem is the wonderful market is full of shortie-pigs. No chance for the so-called market to react appropriately ...
Only one word - AMAZING !!!
Great News dia ...
The only thing that we are able to do ...
Good luck ...
Yes, everything you say is true ... perhaps we will see ...
Do you really think SRNE is so stupid, to apply extensively for a procedure at the FDA, only to learn after a long wait, hey, what you want is not possible. Unbelievable ...
Every morning the same shortie-pig procedure ...
Oh yes, the big market does not recognize sorrento ...
03/29/2021 5:02:31 8.00 72
03/29/2021 5:02:31 8.02 76
03/29/2021 5:02:31 8.03 100
03/29/2021 4:59:15 8.13 50
03/29/2021 4:46:39 8.33 16
03/29/2021 4:27:38 8.36 14
Aceso Life Science Group Ltd
Aceso Life Science Group Limited operates bioscience business. The Company engage in the development, commercialization, sell and distribution of cell-based and biological therapies for the treatment of diseases. Aceso Life Science Group also conducts oil and natural gas business.
CURRENT PRICE
474:HK0.23HKD+0.00+1.77%AS OF 03:42 AM EDT 03/29/2021SEE QUOTE
SECTOR
Industrials
INDUSTRY
Industrial Services
SUB-INDUSTRY
Industrial Support Services
FOUNDED
09/30/2005
ADDRESS
Rm 2501-2509 25F Shui On Centr 6-8 Harbour Road Wanchai Hong Kong (SAR)
PHONE
852-3160-8466
WEBSITE
www.acesogrouphk.com
NO. OF EMPLOYEES
192
Great find Stocktrader, very good ...
Shorties worked with news and without news ...
I wish, you would be one of this patients ...
Love your humor ...
Interview with Dr. Ji at Benziga.
Anyone with account ...
Great doing chxal ... Good luck
Ääääh, I think not so long ...
On the front of ihub we can read many timelines at 1H 2021, thats end of june ...
Sorrento Stock Has Multiple Catalysts in Play; Analyst Says ‘Buy’
Some companies favor a "do one job and do it well" approach. However, that is not the Sorrento Therapeutics (SRNE) way.
While being laser-focused on just one objective can have its advantages, having a wider-based remit can be just as effective, if done well.
That is certainly the opinion of Alliance Global analyst James Molloy when evaluating Sorrento’s prospects.
“SRNE combines one of the most active and promising pipelines in the COVID space with a potentially transformative non-opioid pain pipeline, and adds in a deep oncology pipeline,” the analyst said. “Most of SRNE's pipeline has significant catalysts over the next 1-4 quarters, with multiple late-stage clinical data read-outs and multiple potential Emergency Use Authorization (EUA) launches as well.”
So, what’s on offer from the Sorrento menu in the near-term?
The company has already filed an EUA for COVI-STIX, a 15-minute nasal swab antigen test for SARS-CoV-2, in the US and Mexico, and the test could be launched as early as 1H 2021.
HaHa ...
I am mad as hell and I will not take this anymore!
At most a few more days,
ok, a few more months,
ok, I'll wait ...
Why trashed ?
... the experiments took place outside the human body, in test tubes, and do not provide definitive proof of how effective the spray will prove in nasal passages ...
It has also been approved for sale in New Zealand, and approval is being sought in other countries, including the UK.
The study has been submitted to a leading medical journal for review and publication.
They will produced by May in Israel and UK ...
Ok, we will see ...
Perhaps an important info, we will see ...
Agree with 101 % ...
Ok, thanks ... so we are waiting ...
Is it positiv ?
SORRENTO ANNOUNCES FIRST PATIENT TREATED IN PHASE IB AL AMYLOIDOSIS TRIAL WITH STI-6129, AN ANTI-CD38 ANTIBODY-DRUG CONJUGATE
STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently bound by a proprietary chemical linker to a duostatin tubulin inhibitor.
Amyloid Light Chain (AL) Amyloidosis is an incurable disease with limited treatment options and the potential for the development of resistance to current approaches.
SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the first patient has been treated in its Phase 1b Amyloid Light Chain (AL) Amyloidosis study of STI-6129, an ADC which uses STI-5171, a fully human monoclonal antibody (mAb) from Sorrento’s G-MAB™ library. This study is being conducted as a multicenter, open-label, dose-escalation clinical trial in patients with advanced relapsed and/or refractory systemic amyloid light chain (AL) amyloidosis with a primary objective to identify a Phase 2 dose for STI-6129 based on its safety, preliminary efficacy and pharmacokinetic profile.
STI-6129 is an ADC with covalently bound duostatin tubulin inhibitors (Duostatin 5) using a proprietary site-specific C-LOCK™ chemical linker designed to reduce the premature systemic release of duostatin and avoid the potential for toxicity, particular ocular toxicity, seen with other ADCs, especially first-generation products. STI-6129 has demonstrated an improved therapeutic index in animal models, as compared to traditional non-selective conjugates. STI-6129 has the potential for being a first-line treatment for amyloidosis as well as second line in those patients who have developed daratumumab resistance, an anti-CD38 mAb alone. STI-6129 binds to different epitopes than daratumumab and the addition of the targeted delivery of the duostatin can potentially manage those patients who have become refractory to such treatments.
“Enrollment into our amyloidosis study with STI-6129 is another important milestone for Sorrento, and although delayed due to COVID-19, we are pleased this study has started,” stated Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics. “Together with our CD38 CAR-T and DAR-T programs, STI-6129 has the potential to provide additional therapeutic options for patients in need and we are excited to see how it performs in treating patients with AL amyloidosis. We also are looking forward to further evaluating the safety and efficacy of STI-6129 in a soon to start refractory or relapsing multiple myeloma clinical trial.”
chxal, you have perhaps a valid point, we will see ...
Ok my friend, do you really think the people at Sorrento are so stupid not to know this and still apply for an expensive permit?
Do you really believe that ???
SRNE holds over 8 mill. shares of this company ... Wow ...
https://www.sec.gov/Archives/edgar/data/1326110/000119312521084244/d159616dex991.htm
Very encouraging .... thanks
from a later post ...
191 Antigen-Tests alone in Germany ...
https://antigentest.bfarm.de/ords/f?p=101:100:7974315850130:::::
List of antigen tests for the direct pathogen detection of the coronavirus SARS-CoV-2,
which are the subject of the claim according to § 1 clause 1 in accordance with the "Third Ordinance Amending the Ordinance on the Claim to Certain Tests for the Detection of the Presence of an Infection with the Coronavirus SARS-CoV-2 (Coronavirus Test Ordinance - TestV)".
General information
All data as submitted by the manufacturer, only the information in the respective instructions for use is binding.
Further information on the list provided by the BfArM as well as on the criteria underlying the listing and, if applicable, the deletion from the list can be found on our website on antigen tests for SARS-CoV-2.
The following table shows the original tests with their trade name assigned by the manufacturer or European authorized representative. An overview of the respective German distributors and their possibly different names can be found under the link in the column "German distributor(s)".
The indication "Evaluation PEI" represents the corresponding overview published on the website of the Paul-Ehrlich-Institute (PEI) for the comparative evaluation of the sensitivity of SARS-CoV-2 antigen rapid tests (see PEI website).
"Yes" means that the test has already been evaluated by PEI with positive results.
"No" means that no corresponding test results are available so far.
In case of a negative evaluation by the PEI, the BfArM deletes the corresponding test with all assigned distributors from its list.
... better than puking when he does not, hehe
It would be nice, if our Doc is able to say something in this matter at the CEO Roundtable today ...
The Food and Drug Administration will allow some developers of Covid-19 tests to market their products for regular at-home use without first studying how well the tests perform in people without symptoms.
That is like to get an approval / SRNE here we go ...
Companies can apply for permission to market an over-the-counter test for use at home or at point-of-care if there is evidence the test performs well in people with symptoms of Covid-19 and if repeated testing can help mitigate false results. The agency is issuing a new template for test developers seeking an emergency use authorization for a screening test that is used for repeated testing...
Wow, what I can say, buy, if you can ...